Abstract
Objectives: Recent studies have suggested that long-term diuretic therapy may be associated with increased risk of renal cell carcinoma. This carcinoma is not a common malignancy, but it shares risk factors with the considerably more widespread colon cancer (CC). However, there are no data whether or not a relationship between long-term diuretic therapy and CC mortality exists. In this study we tested the hypothesis that long-term diuretic therapy may be associated with increased CC mortality over a 5.6-year follow-up period.
Subjects and methods: The study sample comprised 14 166 patients aged 45 to 74 years with a previous myocardial infarction and/or stable anginal syndrome, screened for participation in the bezafibrate infarction prevention (BIP) study. There were 2153 patients receiving diuretics and 12 013 patients receiving no diuretics.
Results: During the follow-up 139 (6.5%) new cases of cancer were diagnosed in the diuretic–treated group compared with 622 (5.2%) in the group receiving no diuretics (P = 0.02). Colon cancer mortality was significantly higher in the diuretic-treated patients (0.1 vs 0.5%, P = 0.001), whereas mortality differences for other cancer types were not documented. Multivariate analysis identified diuretics as an independent predictor of increased colon cancer incidence and colon cancer mortality with a hazard ratio (HR) of 2.0 (95% CI 1.2–3.2) for colon cancer incidence and 3.7 (95% CI 1.7–8.3) for mortality. However, the association between diuretic therapy and higher incidence of colon cancer was observed only among non-users of aspirin. A relatively lower colon cancer incidence was observed in the furosemide subgroup, and higher in the small combined amiloride/hydrochlorthiazide subgroup (HR 3.15, 95% CI 1.15–8.65).
Conclusion: Long-term exposure to diuretic therapy may be associated with an increased colon cancer-related mortality.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yu MC et alCigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma J Natl Cancer Inst 1986 77 351–356
Kreiger N et alRisk factors for renal cell carcinoma: results of a population-based case-control study Cancer Causes Control 1993 4 553–558
Hiatt RA, Tolan K, Quesenberry CP Jr Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA) Cancer Causes Control 1994 3 319–325
Weinmann S et alUse of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer Am J Epidemiol 1994 140 792–804
Mellemgaard A et alRisk factors for renal cell carcinoma in Denmark: role of medication and medical history Int J Epidemiol 1994 23 923–930
Chow WH et alRisk of renal cancer in relation to diuretics, antihypertensive drugs, and hypertension Cancer Epidemiol Biomarkers Prev 1995 4 327–331
Voilley N et alThe amiloride-sensitive Na+ channel: from primary structure to function Comp Biochem Physiol A Physiol 1997 118 193–200
Maguire D et alRapid responses to aldosterone in human distal colon Steroids 1999 64 51–63
Ismailov II, Benos DJ Effects of phosphorylation on ion channel function Kidney Int 1995 48 1167–1179
Bonvalet JP, Rossier B, Farman N Distribution of amiloride-sensitive sodium channel in epithelial tissue C R Seances Soc Biol Fil 1995 189 169–177
Grossman E, Messerli FH, Goldbourt U Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999 83 1090–1093
Tenenbaum A et alIs diuretic therapy associated with increased risk of colon cancer? Am J Med 2001 110 143–145
Goldbourt U et alRationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides inpatients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial) Am J Cardiol 1993 71 909–915
Secondary prevention by raising HDL cholesterol and reducing triglycerides inpatients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 2000 102 1–27
International Classification of Diseases Clinical Modification. 9th Revision, vol. I Edwards Bros: Ann Arbor 1981
SAS Institute Inc SAS/STAT. User’s Guide, version 6, 4th edition, volume 2 SAS Institute Inc: Cary, NC 1987
Yaari S, Goldbourt U A SAS program for evaluating person-years of risk on cohort studies Comp Biol Med 1989 19 353–359
SAS/STAT software: changes and enhancements, release 6 07 SAS Institute Inc: Cary, NC, SAS technical report P-229 1992: 620
Trichopoulos D, Lipworth L, Petridou E, Adami H-O Cancer epidemiology by site. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology Lippincott-Raven Publishers: Philadelphia 1997 p 239
Lipkin M, Reddy B, Newmark H, Lamprecht SA Dietary factors in human colorectal cancer Annu Rev Nutr 1999 19 545–586
Read TF, Kodner IJ Colorectal cancer: risk factors and recommendations for early detection Am Fam Physician 1999 59 3083–3092
Slattery ML et alLifestyle and colon cancer: an assessment of factors associated with risk Am J Epidemiol 1999 150 869–877
Mayer RJ Gastrointestinal tract cancer. In: Harrison's Principles of Internal Medicine Mc Graw-Hill Companies, Inc 1998 p 571
Baron JA, Sandler RS Nonsteroidal anti-inflammatory drugs and cancer prevention Annu Rev Med 2000 51 511–523
Strul H, Arber N Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins IMAJ 2000 2 695–702
Ilyas M, Straub J, Tomlinson IP, Bodmer WF Genetic pathways in colorectal and other cancers Eur J Cancer 1999 35 335–351
Hofhaus G, Gattermann N Mitochondria harbouring mutant mtDNA – a cuckoo in the nest? Biol Chem 1999 380 871–877
Moore MA, Park CB, Tsuda H European registry comparison provide evidence of shared risk factors for renal, colon and gallbladder cancer development Eur J Cancer Prev 1999 8 137–146
Bucher JR et alToxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. 2. Furosemide J Appl Toxicol 1990 10 369–378
Loffing J et alThiazide treatment of rats provokes apoptosis in distal tubule cells Kidney Int 1996 50 1180–1190
Lijinsky W, Reuber MD Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats Toxicol Ind Health 1987 3 413–422
Bucher JR et alToxicology and carcinogenicitystudies of diuretics in F344 rats and B6C3F1 mice. 1.Hydrochlorothiazide J Appl Toxicol 1990 10 359–367
Gold B, Mirvish SS N-Nitroso derivatives of hydrochlorothiazide, niridazole, and tolbutamide Toxicol Appl Pharmacol 1977 40 131–136
Lijinsky W, Epstein SS Nitrosamines as environmental carcinogens Nature 1970 40 131–136
Morrow LE, Grimsley EW Long-term diuertic therapy in hypertensivepatients: effects on serum homo-cysteine, vitamin B6, vitamin B12, and red blood cellfolate concentrations South Med J 1999 92 866–870
Lewis DF, Ioannides C, Parke DV A prospectivetoxicity evaluation (COMPACT) on 40 chemicalscurrently being tested by the National ToxicologyProgram Mutagenesis 1990 5 433–435
Manson JM, Guerriero FJ, Brown T, San Sebastian J Lack of in vivo mutagenicity and testicular toxicity of triamtiren in mice Fundam Appl Toxicol 1986 7 533–546
Shapiro JA et alHypertension, antihypertensive medication use, and risk of renal cell carcinoma Am J Epidemiol 1999 149 521–530
Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B Obesity, hypertension, and the risk of kidney cancer in men N Engl J Med 2000 343 1305–1311
Medical Research Council Working Party MRC trial of treatment of mild hypertension: principal results Br Med J 1985 291 97–104
Fagard RH et alResponse to antihypertensive therapy in olderpatients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Circulation 2000 102 1139–1144
Staessen JA, Wang JG, Thijs L, Fagard R Overview of the outcome trials in olderpatients with isolated systolic hypertension J Hum Hypertens 1999 13 859–863
Joint National Committee The Sixth Report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC-VI) Arch Intern Med 1997 157 2413–2446
Messerli FH, Grossman E, Goldbourt U Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review JAMA 1998 279 1903–1907
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tenenbaum, A., Grossman, E., Fisman, E. et al. Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up. J Hum Hypertens 15, 373–379 (2001). https://doi.org/10.1038/sj.jhh.1001192
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001192
Keywords
This article is cited by
-
Anti-hypertensive medications and risk of colorectal cancer: a systematic review and meta-analysis
Cancer Causes & Control (2022)
-
Carcinogenicity of antihypertensive therapy
Current Hypertension Reports (2002)